You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
DL-AP5 Sodium salt
Sodium salt of DL-AP5 (Cat. No. 0105). Potent NMDA antagonist.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 219.11. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.56 mL||22.82 mL||45.64 mL|
|5 mM||0.91 mL||4.56 mL||9.13 mL|
|10 mM||0.46 mL||2.28 mL||4.56 mL|
|50 mM||0.09 mL||0.46 mL||0.91 mL|
References are publications that support the biological activity of the product.
Evans et al (1982) The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 75 65 PMID: 7042024
Davies and Watkins (1982) Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 235 378 PMID: 6145492
If you know of a relevant reference for DL-AP5 Sodium salt, please let us know.
View Related Products by Product Action
Keywords: DL-AP5 Sodium salt, DL-AP5 Sodium salt supplier, Broad, spectrum, EAA, antagonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, NMDA, 3693, Tocris Bioscience
7 Citations for DL-AP5 Sodium salt
Citations are publications that use Tocris products. Selected citations for DL-AP5 Sodium salt include:
Falgairolle and O'Donovan (2015) Pharmacological Investigation of Fluoro-Gold Entry into Spinal Neurons. Purinergic Signal 10 e0131430 PMID: 26102354
Zhao et al (2018) Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. iScience 6 138 PMID: 30240608
Athilingam et al (2017) Serotonin enhances excitability and gamma frequency temporal integration in mouse prefrontal fast-spiking interneurons. Elife 6 PMID: 29206101
Maschi and Klyachko (2017) Spatiotemporal Regulation of Synaptic Vesicle Fusion Sites in Central Synapses. Neuron 94 65 PMID: 28343869
Thomsen et al (2016) Fixed single-cell transcriptomic characterization of human radial glial diversity. Sci Rep 13 87 PMID: 26524239
Pan et al (2016) Postnatal development of the electrophysiological properties of somatostatin interneurons in the anterior cingulate cortex of mice. PLoS One 6 28137 PMID: 27319800
Cazares et al (2016) Dynamic Partitioning of Synaptic Vesicle Pools by the SNARE-Binding Protein Tomosyn. J Neurosci 36 11208 PMID: 27807164
Do you know of a great paper that uses DL-AP5 Sodium salt from Tocris? Please let us know.
Reviews for DL-AP5 Sodium salt
Average Rating: 5 (Based on 2 Reviews.)
Have you used DL-AP5 Sodium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
DL-AP5 (40 micromolar) blocked spontaneous excitatory postsynaptic currents in an ex-vivo slice preparation.
This small molecule was used as NMDA glutamate site antagonist in ex-vivo patch clamp electrophysiology to investigate neuronal excitability.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.